NCT07009067 Safety and Efficacy of Exercise in Type-B Aortic Dissection
| NCT ID | NCT07009067 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangdong Provincial People's Hospital |
| Condition | Type B Aortic Dissection |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-05-06 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-05-06 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study. The goal of this clinical trial is to evaluate the safety and efficacy of exercise-based cardiac rehabilitation in patients with Type-B Aortic dissection or intramural hematoma or penetrating ulcer and received endovascular repair. The main questions it aims to answer are: • Is exercise-based cardiac rehabilitation safe among these patients? Participants will be randomly assigned to receive usual care plus exercise-based cardiac rehabilitation (guided exercise for 3 months in rehabilitation center) or usual care.
Eligibility Criteria
Inclusion Criteria: * Patients with a previous diagnosis of type B aortic dissection or intramural hematoma or penetrating ulcer, who underwent endovascular aortic repair (EVAR) or EVAR + supra-aortic shunt surgery for more than 1 month, and no related complications (such as endoleak, stent thrombosis, dissection progression, etc.) were found in the postoperative aortic CTA; * Able to independently carry out basic daily life activities, participants must be able to complete the baseline assessment and start the designated treatment; * Patients voluntarily participate in this study, sign the written informed consent, and are willing to cooperate with the follow-up; Exclusion Criteria: * Acute myocardial infarction occurred 1 month ago; * Combined with severe aortic stenosis or regurgitation; * Combined with ascending aortic aneurysm or dissection; * Acute heart failure occurred 2 weeks ago; * Combined with severe hypertrophic obstructive cardiomyopathy; * Chronic renal failure stage 5, which is defined as glomerular filtration rate \<15ml/(min·1.73m2) or dialysis; * During the screening examination, the patient's alanine aminotransferase or aspartate aminotransferase is greater than or equal to 5 times the upper limit of the normal value specified by our center; * Patients with any medical history that may affect compliance with the program; * Patients with severe language, mental or physical disabilities who are unable to participate in the program; * Pregnant or lactating women, or those with fertility who are unwilling/unable to take effective contraceptive measures; * Patients participating in other interventional clinical trials; * Patients with long-term high-intensity exercise habits; * Patients who are judged by the researchers to be unsuitable for participation in this study;
Frequently Asked Questions
Who can join the NCT07009067 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Type B Aortic Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07009067 currently recruiting?
Yes, NCT07009067 is actively recruiting participants. Visit ClinicalTrials.gov or contact Guangdong Provincial People's Hospital to inquire about joining.
Where is the NCT07009067 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07009067 clinical trial?
NCT07009067 is sponsored by Guangdong Provincial People's Hospital. The trial plans to enroll 20 participants.